Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Pancreatic Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Klatskin Tumor 1Glioblastoma 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 20Gemcitabine 10Nivolumab 8Irinotecan 8atezolizumab 7durvalumab 6Docetaxel 6sargramostim 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5aldesleukin 4Psychiatric Rehabilitation 4Leucovorin 4Ipilimumab 4Fluorouracil 4Cisplatin 4tislelizumab 3spartalizumab 3avelumab 3Topotecan 3Therapeutics 3Polymerase Chain Reaction 3Carboplatin 3Bevacizumab 3tremelimumab 2talazoparib 2surufatinib 2regorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × sacituzumab govitecan × Gastrointestinal × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡